An observational study in Apnea, Obstructive, sponsored by AGIR à Dom. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-01.
Sponsored by AGIR à Dom · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 201 studies in Sleep Apnea, Obstructive with a site in France — 39 open to participants now, 48 under way, 4 of them phase 3. Sleep Apnea, Obstructive · France.
Among the 201 studies in Sleep Apnea, Obstructive with a site in France, this one is the 63rd largest by enrollment of the 67 observational ones that give a count, is one of 17 that started in 2021, is one of 67 observational ones, and was the 140th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →39 of the 201 studies in Sleep Apnea, Obstructive with a site in France are open now. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18–75
Hospices Civils de Lyon · Sites in France
Ages 4–17
University Hospital, Grenoble · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–84
Hospices Civils de Lyon · Sites in France
Ages 5 mo–6 mo
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
201 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 17 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 52 across the 133 interventional studies, 140 across the 67 observational. Of the 121 that completed or were terminated, 6 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 201 have an industry lead sponsor. The 10 most frequent:
AGIR à Dom is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
AGIR à Dom has 5 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
13 of the studies in Sleep Apnea, Obstructive with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07283289Centre Hospitalier Intercommunal de Toulon La Seyne sur MerPrevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease | 2026-11 |
| NCT05939934University Hospital, AngersImpact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal | 2026-11 |
| NCT07792746Clinique du MillenaireSleep Apnea Biomarkers and Adherence to Continuous Positive Airway Pressure | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 201 studies in Sleep Apnea, Obstructive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnea syndrome (OSA). It consists of a pressure generator connected to a mask applied to the patient's face. CPAP treatment is restrictive, and nearly a quarter of patients abandon it over the long term. Various factors can influence adherence to CPAP therapy, including adverse events associated with the mask. However, it is clear that compliance with CPAP treatment, even if it has tended to improve over the last 30 years, is still sub-optimal.
The "Air Liquide Medical Systems" company has developed a mask that aims to improve comfort and ease of use for the patient. This leaky nasal mask has a "silent" intentional leak port, which significantly reduces the noise caused by the escape of air. The noise associated with intentional leakage is one of the discomforts reported by patients and their spouses. In addition, this mask is equipped with a new generation headgear with adjustment indicators to assist the patient in fitting the mask. Optimal headgear fit is a prerequisite for comfort during treatment, as it reduces unintentional leakage.
The main objective is to evaluate, through a questionnaire, the comfort and general appreciation of a nasal mask equipped with a silent leak system and a headgear with adjustment aids, of patients with OSA treated with CPAP.
Secondary objectives are :
Continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnea syndrome (OSA). It consists of a pressure generator connected to a mask applied to the patient's face. CPAP treatment is restrictive, and nearly a quarter of patients abandon it over the long term. Various factors can influence adherence to CPAP therapy, including adverse events associated with the mask. Unintentional leaks, i.e. a leak between the pressure generator and the patient's upper airway, are among the most frequent. Therefore, optimizing the choice of mask is one of the main means used by medical-technical providers, in charge of installing CPAP and its technical follow-up at home. In order to cover the needs and anatomical particularities of the OSA patient population treated with CPAP, a large number of mask types and sizes are currently available on the market. However, it is clear that compliance with CPAP treatment, even if it has tended to improve over the last 30 years, is still sub-optimal.
The "Air Liquide Medical Systems" company has developed a mask that aims to improve comfort and ease of use for the patient. This leaky nasal mask has a "silent" intentional leak port, which significantly reduces the noise caused by the escape of air. The noise associated with intentional leakage is one of the discomforts reported by patients and their spouses. In addition, this mask is equipped with a new generation headgear with adjustment indicators to assist the patient in fitting the mask. Optimal headgear fit is a prerequisite for comfort during treatment, as it reduces unintentional leakage.
The main objective is to evaluate, through a questionnaire, the comfort and general appreciation of a nasal mask equipped with a silent leak system and a headgear with adjustment aids, of patients with OSA treated with CPAP.
After 30 days of use, secondary objectives are :
OSA patient, not previously treated with CPAP, who will be treated with a ResMed Airsense 10 CPAP and an Air Liquide Medical Systems NINA mask Patient whose CPAP treatment will be installed and monitored by the home care provider AGIRADOM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
OSA patient, not previously treated with CPAP, are treated with a "ResMed Airsense 10" CPAP and an "Air Liquide Medical Systems" NINA mask during 30 days, monitored by the home care provider AGIRADOM. After 30 days of CPAP treatment, 4 self-questionnaires are completed by the patient and parameters of the CPAP treatment (compliance, estimated unintentional leakage and therapeutic pressures) are collected.
Other: Self-questionnaire on the comfort and general appreciation of a nasal mask · Other: Self-questionnaire on the appearance of CPAP side effects related to the mask · Other: Self-questionnaire on the patient's appreciation of the mask headgear, · Other: Self-questionnaire NOSE on the discomfort caused by the nasal obstruction · Other: Self-questionnaire Epworth on the daytime sleepiness · Other: To study the CPAP compliance · Other: To study the unintentional leakage · Other: To study the therapeutic pressures of CPAP
Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use
Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use
Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.
Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.
Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion. To study the parameters of the CPAP treatment.
To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.
To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
To evaluate the comfort and general appreciation of a nasal mask
to evaluate, through a questionnaire, the comfort and general appreciation of a nasal mask equipped with a silent leak system and a headgear with adjustment aids, of patients with OSA treated with CPAP.
Time frame: After 30 days of CPAP treatment
To evaluate the appearance of CPAP side effects related to the mask
To evaluate the appearance of CPAP side effects, through a questionnaire, related to the mask (air leaks, injury to the nasal bridge, etc.)
Time frame: After 30 days of CPAP treatment
To collect the patient's appreciation of the mask headgear
To collect, through a questionnaire, the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask.
Time frame: After 30 days of CPAP treatment
To evaluate the discomfort caused by the nasal obstruction reported by the patient
To evaluate, trough the NOSE questionnaire, the discomfort caused by the nasal obstruction reported by the patient, compared to the inclusion.
Time frame: After 30 days of CPAP treatment
To evaluate the daytime sleepiness of the patient
To evaluate the daytime sleepiness of the patient, through the Epworth questionnaire, compared to the inclusion.
Time frame: After 30 days of CPAP treatment
To collect the CPAP treatment compliance
To collect the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.
Time frame: During the 30 days of CPAP treatment
To collect the unintentional leakage
To collect the unintentional leakage estimated by the CPAP machine.
Time frame: During the 30 days of CPAP treatment
To collect the CPAP therapeutic pressures
To collect the CPAP therapeutic pressures used.
Time frame: During the 30 days of CPAP treatment
Ran from Sep 2021 to primary completion in Jan 2022, 3 months.
Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's 3 months is below that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AGIR à Dom